🔬 Omniscope Joins Yellow4FLAVI as 14th Partner with the European Commission’s Hop-On Initiative

🌍 We’re proud to announce that Omniscope, based in Malta, has joined Yellow4FLAVI through the Hop-On Facility, expanding our Horizon Europe consortium to 14 partners across 8 countries.

The Hop-On Facility is a Horizon Europe mechanism that enables organisations from underrepresented EU member states to join already-funded projects. Its aim is to strengthen inclusiveness and broaden the impact of European research by integrating new partners with complementary expertise.

This expansion further strengthens our international collaboration and shared commitment to advancing vaccine research against flaviviruses.

🧬 Omniscope is a biotechnology company that specializes in high-throughput immune profiling. Using advanced technologies to sequence T and B cell receptors, their platform helps decode the complexity of immune responses. This approach enables detailed analysis of the immune system across a wide range of diseases, supporting both research and clinical applications in immunology, infectious diseases, and oncology.

💡Omniscope will apply its expertise in receptor sequencing as part of Work Package 3, leading a new Task on Deep Immune Repertoire Analysis to Correlate Protective Immunity, to deepen our understanding of immune responses to the yellow fever 17D vaccine.

📢 The team has already actively participated in the consortium’s governance, including attending the last General Assembly and Steering Committee online meetings, reinforcing their early engagement and integration into the project.

🌐 You can now find their dedicated profile on the Yellow4FLAVI consortium page, highlighting their roles and contributions to the project.

🤝 We look forward to this new collaboration and to the valuable insights Omniscope will bring to Yellow4FLAVI’s mission to inform next-generation vaccine design for yellow fever and other flaviviruses such as dengue, Zika, and West Nile.